In February, the FDA issued a drug safety communication on tofacitinib (Xeljanz), an oral, small-molecule Janus kinase (JAK) inhibitor. According to the FDA communication, a clinical trial in patients with rheumatoid arthritis who were taking an as-yet unapproved 10-mg dose of tofacitinib twice each day found an increased risk of blood clots and death.
In February, the FDA issued a drug safety communication on tofacitinib (Xeljanz), an oral, small-molecule Janus kinase (JAK) inhibitor. According to the FDA communication, a clinical trial in patients with rheumatoid arthritis (RA) who were taking an as-yet unapproved 10-mg dose of tofacitinib twice each day found an increased risk of blood clots and death.
Pfizer, maker of tofacitinib, announced that it has taken steps to transition the patients involved in the study—an ongoing, open-label study evaluating the safety of tofacitinib at 2 doses versus a control group of patients receiving an anti—tumor necrosis factor (anti-TNF)—to the approved 5-mg twice-daily dose. Pfizer noted that similar safety signals were not identified in other clinical trials in RA or in routine monitoring of safety data.
Tofacitinib, which is approved to treat RA, psoriatic arthritis, and ulcerative colitis, has been widely expected to compete with innovator anti-TNF therapies and their emerging biosimilars. Studies have demonstrated that the JAK inhibitor could result in a lower cost to treat RA than cycling anti-TNF drugs in the case of nonresponse, and for many patients, an oral therapy is preferable to either infusion of products like infliximab and its biosimilars or self-administration of injectable biologics like adalimumab (Humira) or etanercept (Enbrel). Additionally, in cases in which ensuring a cold chain for the storage of biologics is difficult, oral small-molecule drugs may be advantageous.
However, JAK inhibitors as a class have come under increased scrutiny in recent months; in April 2018, the FDA’s Arthritis Advisory Committee voted to recommend a low dose of Eli Lilly’s JAK inhibitor, baricitinib, but voted against recommending approval of a higher dose given concerns about the potential for dose-dependent adverse events such as thrombosis.
The drug was later approved by the FDA at the lower dose, under the name Olumiant, with a black box warning that includes a caution related to deep venous thrombosis, pulmonary embolism, and arterial thrombosis, among other warnings.
AbbVie’s proposed JAK inhibitor, upadacitinib, which the company hopes to launch in 6 US indications by 2022 (ahead of biosimilar competition for the company’s flagship RA drug, Humira), could see increased scrutiny from regulators during its priority review. In a phase 3 trial, 1 patient taking a 15-mg dose of the drug had a fatal hemorrhagic stroke caused by a ruptured aneurysm, and there was also 1 event of pulmonary embolism in the study, also in a patient taking a 15-mg dose of the drug.
Ongoing concerns about JAK inhibitors with respect to safety could potentially be a boon for biosimilars of anti-TNF drugs. Biosimilars may allow for substantial cost savings versus their reference products, especially once biosimilars of adalimumab and etanercept reach US patients, and with established safety profiles, anti-TNFs could continue to lead in the inflammatory disease space.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).